What is REGiMMUNE?
REGiMMUNE is a specialized biotechnology firm focused on the development of innovative treatments for immune disorders. By leveraging the patient's own immune system, the company aims to induce immune tolerance and achieve robust anti-tumor responses. Their core competency lies in the sophisticated modulation of regulatory T cells, a critical component in managing autoimmune conditions and enhancing cancer immunotherapy efficacy. The company serves a critical market need, providing advanced therapeutic options for patients who have historically lacked effective treatment pathways for chronic immune-mediated diseases.
How much funding has REGiMMUNE raised?
REGiMMUNE has raised a total of $26M across 5 funding rounds:
Angel/Seed
$1.6M
Series A
$4.2M
Series B
$6M
Series C
$5M
Series D
$9.2M
Angel/Seed (2006): $1.6M with participation from Japan Asia Investment
Series A (2007): $4.2M led by Yasuda Enterprise Development, Mitsubishi Corporation, Fund Creation, Japan Asia Investment, Orix Capital Corporation, and Jafco Ventures
Series B (2008): $6M supported by Yasuda Enterprise Development, Fund Creation, Japan Asia Investment, Friendly Partners, and AC Ventures
Series C (2012): $5M featuring DaiwaEnterprise, Japan Asia Investment Co., Medinet Co., SMBC Venture Capital, and Shinkin Capital
Series D (2014): $9.2M backed by Nippon Venture Capital, SMBC Venture Capital Co., Ltd., Mitsui Sumitomo Insurance, Japan Asia Investment Co., and Mizuho Capital
Key Investors in REGiMMUNE
Japan Asia Investment Co.
An investment firm connecting Japan and Asia, focusing on sectors including healthcare and innovative technology to foster future-ready enterprises.
Yasuda Enterprise Development
A Tokyo-based venture capital and private equity firm dedicated to supporting the growth of emerging companies through strategic financial backing.
SMBC Venture Capital Co., Ltd.
A core financial institution within the Sumitomo Mitsui Financial Group, providing comprehensive investment banking and venture support to corporate entities.
What's next for REGiMMUNE?
With the support of its institutional backers, REGiMMUNE is poised to transition its lead candidates through critical clinical milestones. The strategic focus remains on scaling manufacturing capabilities and expanding the reach of its immune modulation technology. As the company matures, the emphasis will likely shift toward potential commercialization partnerships and the further validation of its platform in diverse therapeutic areas. The current funding environment suggests a strong commitment to long-term value creation, with the firm well-positioned to address the unmet needs of patients suffering from severe immune-related conditions through continued scientific rigor and clinical execution.
See full REGiMMUNE company page
